Pathogenetic background for treatment of ascites and hepatorenal syndrome

Hepatology International

Volumn 2, Issue 4, 2008, Pages 416-428

  Møller, Søren ^a   Henriksen, Jens H ^a   Bendtsen, Flemming ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Hepatic decompensation; Hyperdynamic circulation; Portal hypertension

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; AMILORIDE; AMOXICILLIN PLUS CLAVULANIC ACID; CEFONICID; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DIURETIC AGENT; DOPAMINE; FUROSEMIDE; LOOP DIURETIC AGENT; LOSARTAN; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PLASMA SUBSTITUTE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOMATOSTATIN; SPIRONOLACTONE; TERLIPRESSIN; THIAZIDE DIURETIC AGENT; VASOCONSTRICTOR AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

ASCITES; BACTERIAL PERITONITIS; CLINICAL TRIAL; DRUG DOSE INCREASE; ECHOGRAPHY; ESCHERICHIA COLI; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM EXCRETION; SODIUM RESTRICTION; SPLANCHNIC BLOOD FLOW; STREPTOCOCCUS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 57149118002     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9100-3     Document Type: Review

References (122)

1. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350(16):1646-1654
2. Henriksen JH, Müller S. Alterations of hepatic and splanchnic microvascular exchange in cirrhosis: Local factors in the formation of ascites. In Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell; 2005. 174-185
3. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S69-S89
4. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34(1):46-52
5. Guevara M, Cardenas A, Ginés P. Prognosis of patients with cirrhosis and ascites. In Ginés P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell; 2005. 260-270
6. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41(3):422-433
7. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46(5):935-946
8. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001;49(5):729-737
9. Gentilini P, Vizzutti F, Gentilini A, Zipoli M, Foschi M, Romanelli RG. Update on ascites and hepatorenal syndrome. Dig Liver Dis 2002;34(8):592-605
10. Bernardi M, Caraceni P. Pathogenesis of ascites and hepatorenal syndrome: Altered haemodynamics and neurohumoral systems. In Gerbes AL, Beuers U, Jungst D, Pape G, Sackmann M, Sauerbruch T, editors. Hepatology 2000. Falk Symposium 117, Munich, May 6, 2000. Dordrecht: Kluwer Academic Publishers; 2001. 185-203
11. Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol 2007;18(7):2028-2031
12. Kravetz D, Bildozola M, Argonz J, Romero G, Korula J, Munoz A, et al. Patients with ascites have higher variceal pressure and wall tension than patients without ascites. Am J Gastroenterol 2000;95(7):1770-1775
13. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003;38:S54-S68
14. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology 2006;43(2 Suppl 1):S121-S131
15. Müller S, Henriksen JH. The systemic circulation in cirrhosis. In Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell; 2005. 139-155
16. Henriksen JH, Siemssen O, Krintel JJ, Malchow-Müller A, Bendtsen F, Ring-Larsen H. Dynamics of albumin in plasma and ascitic fluid in patients with cirrhosis. J Hepatol 2001;34(1):53-60
17. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55(Suppl 6):vI1-vi12
18. Casado M, Bosch J, Garciapagan JC, Bru C, Banares R, Bandi JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998;114(6):1296-1303
19. Liu H, Schuelert N, McDougall JJ, Lee SS. Central neural activation of hyperdynamic circulation in portal hypertensive rats depends on vagal afferent nerves. Gut 2008;57:966-973
20. Wiest R. Splanchnic and systemic vasodilation: The experimental models. J Clin Gastroenterol 2007;41(10 Suppl 3):S272-S287
21. Ruiz-Del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-447
22. Ferguson JW, Dover A, Chia S, Cruden N, Hayes PC, Newby D. Inducible nitric oxide synthase activity contributes to the regulation of peripheral vascular tone in patients with cirrhosis and ascites. Gut 2005;55(4):542-546
23. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007;46:927-934
24. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology 2002;35(2):478-491
25. Henriksen JH, Müller S. Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. In Epstein M, editor. The Kidney in Liver Disease. Philadelphia: Hanley & Belfus; 1996. 241-258
26. Farzaneh-Far R, Moore K. Nitric oxide and the liver. Liver 2001;21(3):161-174
27. Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. J Hepatol 2003;38(1):44-50
28. Müller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57(2):268-278
29. Henriksen JH, Müller S, Schifter S, Abrahamsen J, Becker U. High arterial compliance in cirrhosis is related to elevated circulating calcitonin gene-related peptide (CGRP) and low adrenaline, but not to activated vasoconstrictor systems. Gut 2001;49:112-118
30. Levy M. Pathogenesis of sodium retention in early cirrhosis of the liver: Evidence for vascular overfilling. Semin Liver Dis 1994;14:4-13
31. La Villa G, Salmeron JM, Arroyo V, Bosch J, Gines P, Garcia-Pagan JC, et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992;102:2114-2119
32. Bernardi M, Li BS, Arienti V, de Collibus C, Scialpi C, Boriani L, et al. Systemic and regional hemodynamics in pre-ascitic cirrhosis: Effects of posture. J Hepatol 2003;39(4):502-508
33. Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE. Urinary sodium balance in patients with cirrhosis: Relationship to quantitative parameters of liver function. Hepatology 1997;26:1149-1155
34. Müller S, Henriksen JH. Pathogenesis and pathophysiology of hepatorenal syndrome'is there scope for prevention? Aliment Pharmacol Ther 2004;20(Suppl 3):31-41
35. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006;44(6):1535-1542
36. Bernardi M, Matco CD, Trevisani F, Collibus CD, Fornalé L, Baraldini M, et al. The hemodynamic status of preascitic cirrhosis: An evaluation under steady-state conditions and after postural change. Hepatology 1992;16:341-346
37. Sansoe G, Ferrari A, Baraldi E, Castellana CN, De Santis MC, Manenti F. Renal distal tubular handling of sodium in central fluid volume homoeostasis in preascitic cirrhosis. Gut 1999;45(5):750-755
38. Claria J, Rodes J. Renal sodium handling in preascitic cirrhosis. Gut 2001;48(5):740-741
39. Pozzi M, Grassi G, Redaelli E, Dell'Oro R, Ratti L, Redaelli A, et al. Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis. Hepatology 2001;34(6):1113-1118
40. Bernardi M, Domenicali M. The renin-angiotensin-aldosterone system in cirrhosis. In Ginés P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and Renal Dysfunction in Liver Disease. Malden: Blackwell; 2005. p. 43-54
41. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362(9398):1819-1827
42. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28(1):81-95
43. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-176
44. Ring-Larsen H. Renal blood flow in cirrhosis: Relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977;37:635-642
45. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34(1):19-27
46. Epstein M. Renal sodium handling in liver disease. In Epstein M, editor. The Kidney in Liver Disease. Philadelphia: Hanley & Belfus; 1996. 1-31
47. Gerbes AL, Gulberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998;28(3):683-688
48. Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: A randomised pilot study. Gut 2002;50(1):90-94
49. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123(6):1839-1847
50. Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin Liver Dis 1994;14(1):71-81
51. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002;122(6):1658-1676
52. Marik PE, Wood K, Starzl TE. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transpl 2006;21(2):478-482
53. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: Evidence for the existence of a hepatorenal reflex in man? Gut 1997;40:664-670
54. Kapoor D, Redhead DN, Hayes PC, Webb DJ, Jalan R. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003;9(1):32-39
55. Müller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998;58(5):361-372
56. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral artery vasodilatation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151-1157
57. Henriksen JH, Ring-Larsen H. Hepatorenal disorders: Role of the sympathetic nervous system. Semin Liver Dis 1994;14:35-43
58. Henriksen JH. Cirrhosis: Ascites and hepatorenal syndrome. Recent advances in pathogenesis. J Hepatol 1995;23:25-30
59. Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology 2008;47(1):160-168
60. Stadlbauer VP, Wright GA, Banaji M, Mukhopadhya A, Mookerjee R, Moore K, et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008;134(1):111-119
61. Dagher L, Patch D, Marley R, Moore K, Burroughs A. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 2000;14(5):515-521
62. Llach J, Ginés P, Arroyo V, Rimola A, Titó L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-487
63. Ruiz-Del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38(5):1210-1218
64. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008;28(1):59-69
65. Krag A, Bendtsen F, Henriksen JH, Müller S. Low cardiac index predicts survival and renal failure in patients with ascites. Evidence of a heart-kidney axis in cirrhosis. J Hepatol 2008;48:S118
66. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 2003;37(1):182-191
67. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology 2003;124(4):933-939
68. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008;28(1):26-42
69. Salerno F, Restelli B, Incerti P, Annoni G, Capozza L, Badalamenti S, et al. Utility of ascitic fluid analysis in patients with malignancy-related ascites. Scand J Gastroenterol 1990;25(3):251-256
70. Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure: Effect of posture. BMJ 1986;292:1351-1353
71. Gines P, Cardenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008;28(1):43-58
72. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology 2003;38(1):258-266
73. Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997;26(3):614-620
74. Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991;13(4):707-713
75. Fassio E, Terg R, Landeira G, Abecasis R, Salemne M, Podesta A, et al. Paracentesis with dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J Hepatol 1992;14(2-3):310-316
76. Altman C, Bernard B, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 1998;10(1):5-10
77. Planas R, Gines P, Arroyo V, Llach J, Panes J, Vargas V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Gastroenterology 1990;99:1736-1744
78. Cabrera J, Falcon L, Gorriz E, Pardo MD, Granados R, Quinones A, et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. Gut 2001;48(3):384-389
79. Pozzi M, Ratti L, Redaelli E, Guidi C, Mancia G. Cardiovascular abnormalities in special conditions of advanced cirrhosis. The circulatory adaptative changes to specific therapeutic procedures for the management of refractory ascites. Gastroenterol Hepatol 2006;29:263-272
80. Gines P, Guevara M, De Las HD, Arroyo V. Review article: Albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002;16(Suppl 5):24-31
81. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37(5):1147-1153
82. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-1010
83. Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: A randomised controlled pilot trail. Liver Int 2006;26(1):46-54
84. Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: A randomized pilot study. J Intern Med 2006;260(1):62-68
85. Krag A, Müller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46(6):1863-1871
86. Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: A randomized pilot study. Am J Gastroenterol 2008;103(6):1399-1405
87. D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: A meta-analysis. Gastroenterology 2005;129(4):1282-1293
88. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342(23):1701-1707
89. Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: A meta-analysis of individual patient data. Gastroenterology 2007;133(3):825-834
90. Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006;(4):CD004889
91. Esteva-Font C, Baccaro ME, Fernandez-Llama P, Sans L, Guevara M, Ars E, et al. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: relationship with ascites and hepatorenal syndrome. Hepatology 2006;44(6):1555-1563
92. Gines P. Vaptans: A promising therapy in the management of advanced cirrhosis. J Hepatol 2007;46(6):1150-1152
93. Gerbes AL, Gulberg V. Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol 2006;12(4):516-519
94. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. A consensus workshop of the International Ascites Club. Gut 2007;56:1310-1318
95. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48(Suppl 1):S93-S103
96. Navasa M, Feu F, Garciapagan JC, Jimenez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993;17:355-360
97. Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, et al. Transplantation: Impact of pretransplant renal insufficiency. Liver Transpl 2008;14(5):665-671
98. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28(2):416-422
99. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29(4):565-570
100. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33(1):43-48
101. Müller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20(1):51-59
102. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study. Acta Gastroenterol Belg 2001;64(1):15-19
103. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002;36(4 Pt 1):941-948
104. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122(4):923-930
105. Guevara M, Gines P, Fernandezesparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41
106. Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, Rehling M, Henriksen JH, Pedersen EB, et al. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: A randomized, double-blind, controlled trial. Hepatology 2001;34(3):471-477
107. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 2002;36(2):374-380
108. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38(1):238-243
109. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29(6):1690-1697
110. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40(1):55-64
111. Van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996;24(6):747-752
112. Luca A, Feu F, Garcia-Pagan JC, Jiménez W, Arroyo V, Bosch J, et al. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 1994;20:30-33
113. Ruiz del Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-586
114. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders. Role of the renin-angiotensin-aldosterone system. Semin Liver Dis 1994;14:23-34
115. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993;104:588-594
116. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29(2):334-339
117. Garcia-Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution. Gastroenterology 1999;117(3):740-742
118. Epstein M, Weitzman RE, Preston S, Denunzio AG. Relationship between plasma arginine vasopressin and renal water handling in decompensated cirrhosis. Miner Electrolyte Metab 1984;10:155-165
119. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002;36(5):1197-1205
120. Fernandez-Llama P, Turner R, Dibona G, Knepper MA. Renal expression of aquaporins in liver cirrhosis induced by chronic common bile duct ligation in rats. J Am Soc Nephrol 1999;10(9):1950-1957
121. Claria J, Jimenez W, Arroyo V, La Villa G, Lopez C, Asbert M, et al. Effect of V-1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991;100:494-501
122. Morales J, Moitinho E, Abraldes JG, Fernandez M, Bosch J. Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. Hepatology 2003;38(6):1378-1383